IOVAIovance Biotherapeutics, Inc.

IOVA Stock Price, Valuation & Chart | Iovance Biotherapeutics, Inc.

Compare

$8.620+0.34 (+4.11%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IOVA intrinsic value IOVA calculated fair value vs price

Overview Financials Dividends Ratios

IOVA Historical price chart

IOVA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.85B

PE Ratio-11.81

EPS-0.73

Trading Volume12.29M

Today's High/Low8.69/8.29

Dividend Yield0.00

52 Week High/Low9.36/1.76

Shares Outstanding446.50M

IOVA Financial Statement

IOVA Analyst ratings

IOVA Analysis & performance metrics

IOVA Company profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a…

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its…

IOVA Management team

Name

Position

Tracy Winton

Executive Vice President of Human Resources

Igor P. Bilinsky Ph.D.COO

Chief Operating Officer

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

Friedrich Graf Finckenstein M.D.

Chief Medical Officer

Raj K. Puri M.D., Ph.D.

Chief Regulatory Officer

Howard B. Johnson M.B.A.

Chief Business Officer

Kevin Smyth

Executive Vice President of Quality

Frederick G. Vogt Esq., J.D., Ph.D.CEO

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

Name

Position

Tracy Winton

Executive Vice President of Human Resources

Igor P. Bilinsky Ph.D.COO

Chief Operating Officer

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

Friedrich Graf Finckenstein M.D.

Chief Medical Officer

Raj K. Puri M.D., Ph.D.

Chief Regulatory Officer

Howard B. Johnson M.B.A.

Chief Business Officer

Kevin Smyth

Executive Vice President of Quality

Frederick G. Vogt Esq., J.D., Ph.D.CEO

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

Management Team

Tracy Winton

Executive Vice President of Human Resources

Igor P. Bilinsky Ph.D.COO

Chief Operating Officer

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

Friedrich Graf Finckenstein M.D.

Chief Medical Officer

Raj K. Puri M.D., Ph.D.

Chief Regulatory Officer

Howard B. Johnson M.B.A.

Chief Business Officer

Kevin Smyth

Executive Vice President of Quality

Frederick G. Vogt Esq., J.D., Ph.D.CEO

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

Management

Tracy Winton

Executive Vice President of Human Resources

Igor P. Bilinsky Ph.D.COO

Chief Operating Officer

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

Friedrich Graf Finckenstein M.D.

Chief Medical Officer

Raj K. Puri M.D., Ph.D.

Chief Regulatory Officer

Howard B. Johnson M.B.A.

Chief Business Officer

Kevin Smyth

Executive Vice President of Quality

Frederick G. Vogt Esq., J.D., Ph.D.CEO

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

Total 8 executives

IOVA Frequently asked questions

What is Iovance Biotherapeutics, Inc. (IOVA) Stock Price?

Current stock price of Iovance Biotherapeutics, Inc. (IOVA) stock is $8.620. The stock price is +4.11% higher in the session. The intraday range can be seen from this page. Volume of Iovance Biotherapeutics, Inc. (IOVA) stock is 12.29M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Iovance Biotherapeutics, Inc. (IOVA) stock price going up or down today?

The stock price of Iovance Biotherapeutics, Inc. (IOVA) can change with earnings, company news, and overall market sentiment. Iovance Biotherapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Iovance Biotherapeutics, Inc. stock expensive at its current price?

Whether Iovance Biotherapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IOVA on this page is -11.81. EPS on this page is -0.73. Compare those figures with peers and growth expectations before deciding if the current Iovance Biotherapeutics, Inc. price is justified.

How has the stock price of Iovance Biotherapeutics, Inc. (IOVA) performed historically?

Historical performance for Iovance Biotherapeutics, Inc. (IOVA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IOVA reacted to past earnings and market events.

Should I buy Iovance Biotherapeutics, Inc. (IOVA) stock, at this price?

Buying Iovance Biotherapeutics, Inc. (IOVA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.